Filter posts

Prosensa's IPO and the Value of the BIO Investor Forum

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of …

JOBS Act Provides Innovators with Capital Boost

Despite all the talk of gridlock and polarization in Washington these days, successful, bipartisan pieces …

The Return of the Biotech IPO

It isn’t just the volume of IPOs this summer that makes this window a victory …

BIO-Europe Spring Opening Remarks

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

Indices, IPOs, Approvals - YTD Update Aug 14th, 2012

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed …

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the …

Indices, IPOs, and New Drug Approvals - Update April 3rd 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its …

Biofuels Digest Measures Bioenergy Business Outlook

Biofuels Digest and BIO launched the 2012 Q1 Bioenergy Business Outlook Survey. In the last …